Printer Friendly

BIOMERICA SIGNS CONTRACT FOR DISTRIBUTION OF ULCER TEST IN THE UNITED STATES AND CANADA

 NEWPORT BEACH, Calif., March 9 /PRNewswire/ -- Biomerica Inc. (NASDAQ: BMRA) has announced that it has entered into a marketing agreement with Bio-Rad Laboratories of Hercules, Calif., for the distribution of its gastritis and ulcer test "GAP" in the United States and Canada. Earlier, Biomerica has signed another agreement with Bio-Rad, Italy, for the distribution of GAP in Europe and the Pacific Rim excluding Japan.
 In the Japanese market, Biomerica has already signed up with Nisshin Flour Milling Co./Fujirebio for the distribution of the product. The Nisshin/Fujirebio team is a formidable force in the diagnostic and pharmaceutical markets and will be launching the product this month in Japan, where stomach ulcer and stomach cancer are prevalent. Being the first to obtain approval from the Japanese government, Nisshin/Fujirebio have a definite headstart over the competition.
 The GAP test is a simple, non-invasive blood test for determining if an individual has the H. pylori bacterium, the main cause of gastritis and peptic ulcer as well as stomach cancer. H. pylori is one of the most widespread of all infectious agents. Between 20 percent and 40 percent of the adult population in the United States harbor H. pylori. In the developing countries, the percentage rises to as much as 80 percent to 100 percent. The pervasiveness of H. pylori infection is reflected in the high incidence of ulcers.
 Pioneered by Biomerica, the GAP test offers simplicity and low cost as compared to the unpleasant, tedious, expensive and somewhat equivocal endoscopy method. Endoscopy involves sending a tube containing a flexible fiber optic bundle and tissue sampling apparatus from the mouth to the stomach to obtain a biopsy. The biopsy specimens are then identified by various techniques, most of which are time-consuming. Endoscopy is expensive: It can cost from $800 to several thousand dollars, compared to less than $50 for a blood test.
 With the recent medical findings about the need to eradicate H. pylori completely in order to prevent the recurrence of gastritis and ulcer disease, Biomerica anticipates the generation of significant sales in these markets. The worldwide market potential for the test has been estimated by various sources to be as high as $100 million.
 Biomerica is a medical company engaged in the development, manufacturing and marketing of advanced medical diagnostic products including home self-testing for early diagnosis of many diseases before becoming incurable.
 -0- 3/9/93
 /CONTACT: Joseph Irani, president of Biomerica, 714-645-2111/
 (BMRA)


CO: Biomerica Inc. ST: California IN: MTC SU: PDT

EH -- LA014 -- 4534 03/09/93 12:38 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1993
Words:423
Previous Article:GTE CALIFORNIA OFFERS RETIREMENT INCENTIVES TO EMPLOYEES
Next Article:SPECTRUM SIGNAL PROCESSING REPORTS RECORD QUARTERLY AND YEAR-END RESULTS
Topics:


Related Articles
BIOMERICA SIGNS AN AGREEMENT WITH SAV-ON/OSCO FOR DISTRIBUTION OF STOOL BLOOD TEST KIT
BIOMERICA SIGNS HOOK DRUGS FOR DISTRIBUTION OF STOOL BLOOD TEST KIT
BIOMERICA SIGNS WALGREENS FOR DISTRIBUTION OF STOOL BLOOD TEST KIT
BIOMERICA SIGNS SALES AGREEMENT WITH INTERNATIONAL MEDICAL COMPANY
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
BIOMERICA H. PYLORI TEST SALES SHOULD BENEFIT FROM NIH ANNOUNCEMENT
BIOMERICA AND GIV REACH EXCLUSIVE U.S. MARKETING AND DISTRIBUTION AGREEMENT FOR EZ DETECT(TM) STOOL BLOOD TEST
Biomerica Introduces 10 Minute Test for Ulcer Screening
OraVax Out-Licenses CagA H. pylori Antigen to Biomerica, Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters